ACEI/ARB Use and Risk of Infection or Severity or Mortality of COVID-19: A Systematic Review and Meta-analysis
Review of 14 articles (>19,000 COVID-19 cases) found that ACEI/ARB exposure is not associated with a higher risk of COVID-19 infection, and among those with COVID-19 infection, exposure is not associated with increased severity or mortality.
Source:
Pharmacological Research
SPS commentary:
Authors report that in those with COVID-19 infection, ACEI/ARB exposure was associated with a lower risk of mortality compared those with non-ACEI/ARB antihypertensive drugs (OR = 0.48, 95% CI 0.29-0.81). They suggest that the study supports current professional society guidelines to not discontinue ACEIs or ARBs in the setting of the COVID-19 pandemic or COVID-19 patients.